跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
IL2-CD25
首页
药物
IL2-CD25
IL2-CD25
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ENGINEERED ANTI-IL-2 ANTIBODIES
EP 4103607 A4
申请人: AULOS BIOSCIENCE INC
优先权: 2020
CN
EP
US
WO
9 件公开
BISPECIFIC IMMUNOTOXINS TARGETING HUMAN CD25+CCR4+ TUMORS AND REGULATORY T-CELLS
EP 3927731 A4
申请人: UNIV COLORADO REGENTS
优先权: 2019
EP
US
4 件公开
METHODS OF USE OF ANTI-IL-2 ANTIBODIES
EP 4615868 A4
申请人: AULOS BIOSCIENCE INC
优先权: 2022
EP
US
WO
3 件公开
US 2024287169 A1
申请人: AULOS BIOSCIENCE INC
优先权: 2024
US
ANTI-HUMAN IL-2 MONOCLONAL ANTIBODY AND USE THEREOF
WO 2024077773 A1
申请人: SHENZHEN BAISHITONG TECH DEVELOPMENT COMPANY LIMITED
优先权: 2022
CN
WO
2 件公开
Cancer treatment through suction effect T-cell and loss regulating T-cell
CN 1833724 A
申请人: YANGXIN FU
优先权: 2005
CN
Treating cancer through attracting effect T cell and loss regulating T cell
CN 101095953 A
申请人: BOERCHENG BEIJING TECHNOLOGY I
优先权: 2005
CN
Novel cytokine for virus delivery and application of novel cytokine in tumor treatment
CN 116948005 A
申请人: WANG XIAOXIA
优先权: 2022
CN
Fixed-point modified biased activated interleukin-2 and application thereof
CN 121851139 A
申请人: UNIV BEIJING
优先权: 2024
CN
药物
反馈